Please use this identifier to cite or link to this item:
Title: Alzheimer’s disease normative cerebrospinal fluid biomarkers validated in PET amyloid-β characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study
Austin Authors: Li, Qiao-Xin;Villemagne, Victor L ;Doecke, James D;Rembach, Alan;Sarros, Shannon;Varghese, Shiji;McGlade, Amelia;Laughton, Katrina M;Pertile, Kelly K;Fowler, Christopher J;Rumble, Rebecca L;Trounson, Brett O;Taddei, Kevin;Rainey-Smith, Stephanie R;Laws, Simon M;Robertson, Joanne S;Evered, Lisbeth A;Silbert, Brendan;Ellis, Kathryn A;Rowe, Christopher C ;Macaulay, S Lance;Darby, David G;Martins, Ralph N;Ames, David;Masters, Colin L ;Collins, Steven
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
CSIRO Digital Productivity/Australian e-Health Research Centre and Cooperative Research Centre for Mental Health, Brisbane, Queensland, Australia
Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia
Centre of Excellence for Alzheimer’s Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia
Centre for Anaesthesia and Cognitive Function, Department of Anaesthesia, and Department of Surgery, St. Vincent’s Hospital, The University of Melbourne, Victoria, Australia
The University of Melbourne Academic Unit for Psychiatry of Old Age, St George’s Hospital, Kew, Victoria, Australia
CSIRO Food and Nutrition Flagship, Parkville, Victoria, Australia
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Western Australia, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
Issue Date: 2015 2015-05-29
Publication information: Journal of Alzheimer's Disease 2015; 48(1): 175-187
Abstract: Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42, total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer’s disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11C-Pittsburgh Compound B, 18F-flutemetamol, or 18F-florbetapir, in 157 AIBL participants who also underwent CSF collection. Using an INNOTEST assay, cut-points were established (Aβ1-42 >544 ng/L, T-tau <407 ng/L, and P-tau181P <78 ng/L) employing a rank based method to define a “positive” CSF in the sub-cohort of amyloid-PET negative healthy participants (n = 97), and compared with the presence of PET demonstrated AD pathology. Results: CSF Aβ1-42 was the strongest individual biomarker, detecting cognitively impaired PET positive mild cognitive impairment (MCI)/AD with 85% sensitivity and 91% specificity. The ratio of P-tau181P or T-tau to Aβ1-42 provided greater accuracy, predicting MCI/AD with Aβ pathology with ≥92% sensitivity and specificity. Cross-validated accuracy, using all three biomarkers or the ratio of P-tau or T-tau to Aβ1-42 to predict MCI/AD, reached ≥92% sensitivity and specificity. Conclusions: CSF Aβ1-42 levels and analyte combination ratios demonstrated very high correlation with PET Aβ imaging. Our study offers additional support for CSF biomarkers in the early and accurate detection of AD pathology, including enrichment of patient cohorts for treatment trials even at the pre-symptomatic stage.
DOI: 10.3233/JAD-150247
ORCID: 0000-0003-3910-2453
PubMed URL:
Type: Journal Article
Subjects: Alzheimer disease
Amyloid beta-peptides
Peptide fragments/cerebrovascular fluids
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.